Search results for "Adjuvants"

showing 10 items of 151 documents

Ciamexone in endocrine orbitopathy. A randomized double-blind, placebo-controlled study.

1990

Abstract The influence of ciamexone on the activity and course of endocrine orbitopathy was investigated. Fifty-one patients with active orbitopathy classes II-VI were allocated randomly to two groups: over a period of six months, 26 patients received 300 mg/day ciamexone and 25 patients received placebo tablets. In both groups, prednisolone was administered in addition in the first four weeks. Ophthalmological investigations and clinical tests as well as orbit sonography were carried out before as well as one, three and six months after the beginning of therapy. Before and after treatment, computer tomography of the orbit was performed. Symptoms and signs did not show any significant impro…

AdultMalemedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and Metabolismmedicine.medical_treatmentEye diseasePrednisoloneAziridinesPlacebo-controlled studyVisual AcuityPlaceboRandom AllocationEndocrinologyAdjuvants ImmunologicDouble-Blind MethodInternal medicineOrbital DiseasesMedicineHumansExophthalmusIntraocular PressureAgedChemotherapybiologybusiness.industryThyroiditis AutoimmuneEndocrine orbitopathyGeneral MedicineMiddle Agedbiology.organism_classificationmedicine.diseaseEndocrinologyPrednisoloneCorticosteroidFemalebusinessmedicine.drugActa endocrinologica
researchProduct

[Treatment of sensorineural hearing loss in acute viral otitis media with intratympanic dexamethasone and hyaluronic acid in comparison with intraven…

2006

Background: Intratympanic dexamethasone with hyaluronic acid has shown to be an effective treatment of the inner ear damage in sudden hearing loss and Meniere's disease. It is not known yet if the same applies to the toxic inner ear damage in acute viral otitis media. Patients: Retrospectively, 26 patients who suffered from acute viral otitis media with sensorineural hearing loss were examined with regard to the improvement of their inner ear hearing loss. Twelve patients were treated with intravenous therapy only, consisting of hydroxyethylstarch, pentoxifylline and prednisolone. Fourteen patients additionally received intratympanic injections, consisting of dexamethasone and hyaluronic ac…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentHearing Loss SensorineuralPrednisoloneVasodilator AgentsAnti-Inflammatory AgentsEar MiddleDexamethasonePentoxifyllineInjectionsHydroxyethyl Starch DerivativesAdjuvants ImmunologicAudiometryotorhinolaryngologic diseasesmedicineHumansHyaluronic AcidPentoxifyllineInfusions IntravenousDexamethasoneRetrospective StudiesRound windowmedicine.diagnostic_testbusiness.industryMiddle Agedmedicine.diseaseSurgeryOtitis MediaOtitismedicine.anatomical_structureOtorhinolaryngologyIntravenous therapyAnesthesiaData Interpretation StatisticalAcute DiseasePrednisoloneSensorineural hearing lossDrug Therapy CombinationFemalesense organsmedicine.symptomAudiometrybusinessBone Conductionmedicine.drugLaryngo- rhino- otologie
researchProduct

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared wit…

2011

BACKGROUND: The human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine is immunogenic, has a clinically acceptable safety profile, and prevents incident and persistent HPV-16/18 infection and cervical precancerous lesions. This study (NCT00552279) evaluated the vaccine when administered according to an alternative dosing schedule (0-1-12 months) compared with the standard dosing schedule (0-1-6 months). METHODS: The study was of randomized open design and was conducted at multiple centers in Europe. Healthy women aged 15 to 25 years were randomized (1:1) to receive HPV-16/18 vaccine according to the standard schedule at months 0, 1, and 6 (n = 401) or an alternative schedule at months 0, …

AdultMicrobiology (medical)medicine.medical_specialtyScheduleAdolescentImmunization SecondaryEnzyme-Linked Immunosorbent AssayAntibodies Virallaw.inventionYoung AdultAdjuvants ImmunologicRandomized controlled triallawInternal medicinemedicineHumansPapillomavirus VaccinesDosingHuman papillomavirusYoung adultbusiness.industryImmunogenicityhuman papillomavirus human papillomavirus vaccines adolescent immunology alternative dosing scheduleVaccinationvirus diseasesSettore MED/40 - Ginecologia E Ostetriciafemale genital diseases and pregnancy complicationsEuropeSafety profileInfectious DiseasesImmunizationPediatrics Perinatology and Child HealthImmunologyFemalebusiness
researchProduct

Regulation of immunomodulatory functions by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in vivo

1996

The present study was designed to investigate in vivo immunomodulatory properties of hematopoietic growth factors. The influence on the activation of cytokine synthesis and on the expression of surface antigens associated with cellular activation of G-CSF or GM-CSF was investigated in cancer patients receiving these factors. One single dose of growth factor was administered to patients with bladder cancer (G-CSF group) or small cell lung cancer (GM-CSF group) before chemotherapy. After cytoreductive chemotherapy patients received supportive therapy with G-CSF or GM-CSF. Peripheral blood mononuclear cells and plasma samples were obtained for flow cytometry, Northern blot analysis, and assess…

AdultSialoglycoproteinsmedicine.medical_treatmentBiologyPeripheral blood mononuclear cellAdjuvants ImmunologicGranulocyte Colony-Stimulating FactormedicineHumansRNA MessengerGrowth SubstancesInterleukin 6AgedInterleukin-6MonocyteGrowth factorInterleukin-8Granulocyte-Macrophage Colony-Stimulating FactorReceptors Interleukin-1Receptors Interleukin-2HematologyGeneral MedicineMiddle AgedHematopoietic Stem CellsRecombinant ProteinsGranulocyte colony-stimulating factorInterleukin 1 Receptor Antagonist ProteinHaematopoiesisGranulocyte macrophage colony-stimulating factormedicine.anatomical_structureCytokineSolubilityAntigens SurfaceImmunologyCancer researchbiology.proteinmedicine.drugAnnals of Hematology
researchProduct

The clinical value of PSA increase during intravesical adjuvant therapy for nonmuscle-invasive bladder cancer.

2016

Introduction Prostatic Specific Antigen (PSA), Bacillus Calmette-Guerin (BCG) increase after intravesical BCG has been reported. The need of prostate biopsy in these patients is object of debate. The aim of our study was to evaluate the effect of intravesical therapy on PSA after transurethral resection (TUR) of nonmuscle-invasive bladder cancer (NMIBC). Materials and methods Patients undergoing intravesical chemotherapy or immunotherapy for NMIBC were entered. PSA was measured before TUR, before the first and after the sixth instillation, 30 and 90 days after the last instillation. Patients with PSA ≥4 ng/ml or palpable prostate nodule were excluded. Results Out of 130 patients, 105 were e…

Adultmedicine.medical_specialtyProstate biopsymedicine.medical_treatment030232 urology & nephrologyUrologyAntineoplastic Agents03 medical and health sciencesProstate cancer0302 clinical medicineAdjuvants ImmunologicBiopsyIntravesical instillation Prostate cancer PSAmedicineAdjuvant therapyCombined Modality TherapyHumansNeoplasm InvasivenessAgedAged 80 and overChemotherapyBladder cancermedicine.diagnostic_testbusiness.industryGeneral MedicineImmunotherapyMiddle AgedProstate-Specific Antigenmedicine.diseaseCombined Modality TherapyAdministration IntravesicalUrinary Bladder Neoplasms030220 oncology & carcinogenesisBCG VaccinebusinessUrologia
researchProduct

Is intravesical instillation of hyaluronic acid and chondroitin sulfate useful in preventing recurrent bacterial cystitis? A multicenter case control…

2015

Abstract Objective Urinary tract infections (UTIs) are common in the female population and, over a lifetime, about half of women have at least one episode of UTI requiring antibiotic therapy. The aim of the current study was to compare two different strategies for preventing recurrent bacterial cystitis: intravesical instillation of hyaluronic acid (HA) plus chondroitin sulfate (CS), and antibiotic prophylaxis with sulfamethoxazole plus trimethoprim. Materials and methods This was a retrospective review of two different cohorts of women affected by recurrent bacterial cystitis. Cases (experimental group) were women who received intravesical instillations of a sterile solution of high concen…

Adultmedicine.medical_specialtyRecurrent bacterial cystitismedicine.drug_classUrinary systemCystitiAntibioticsUrinalysislcsh:Gynecology and obstetricsGastroenterologyantibioticsantibiotics; chondroitin sulfate; cystitis; hyaluronic acidchemistry.chemical_compoundAdjuvants ImmunologicRecurrenceInternal medicineObstetrics and GynaecologyHyaluronic acidCystitismedicineHumansChondroitin sulfateAntibiotic prophylaxisHyaluronic Acidlcsh:RG1-991antibiotics chondroitin sulfate cystitis hyaluronic acidchondroitin sulfateRetrospective StudiesDose-Response Relationship Drugbusiness.industrySulfamethoxazoleChondroitin SulfatesAntibioticObstetrics and GynecologySettore MED/40 - Ginecologia E OstetriciaTrimethoprimSurgeryAdministration IntravesicalInstillation DrugchemistryUrinary Tract InfectionsDrug Therapy CombinationFemalebusinessmedicine.drugFollow-Up StudiesTaiwanese journal of obstetricsgynecology
researchProduct

THE OPTIMIZATION OF INTERFERON FOR MS STUDY: 375 MICROG INTERFERON BETA-1B IN SUBOPTIMAL RESPONDERS.

2008

We aimed to evaluate the safety and MRI efficacy of interferon beta-1b (IFNbeta-1b) 375 microg (subcutaneously [sc] every other day [eod]) in relapsing-remitting multiple sclerosis (RRMS) patients with a suboptimal response to IFNbeta-1b 250 microg, i.e., with MRI activity or relapses. The OPTimization of Interferon for MS (OPTIMS) study was a prospective multicenter randomized phase 2 trial comprising a 6-month run-in phase (to identify suboptimal responders) and a 6-month randomized phase of open-label clinical and blinded MRI follow-up. During run-in all patients were treated with IFNbeta-1b 250 microg sc eod; during the study phase suboptimal treatment responders were randomized either …

Adultmedicine.medical_specialtyTime FactorsAdolescentInjections Subcutaneoussuboptimal treatment responseGastroenterologyDrug Administration Schedulelaw.inventionYoung AdultMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicRandomized controlled triallawInternal medicinemedicineHumansSingle-Blind MethodProspective StudiesAdverse effectProspective cohort studyinterferon beta (IFNβ)immunomodulatory drugSubclinical infectionDose-Response Relationship Drugbusiness.industryInterferon beta-1bInterferon-betaMiddle AgedMagnetic Resonance ImagingConfidence intervalSurgeryClinical trialTreatment OutcomeNeurologyRelative riskmultiple sclerosiMRI activitySettore MED/26 - NeurologiaNeurology (clinical)businessFollow-Up StudiesInterferon beta-1b
researchProduct

An alternative allergen:adjuvant formulation potentiates the immunogenicity and reduces allergenicity of a novel subcutaneous immunotherapy product f…

2012

Background Subcutaneous specific immunotherapy (SCIT) has proven sustained clinical efficacy against allergy. The recommended regimen for SCIT is a gradual updosing over a period of weeks. Commonly, in commercial products for SCIT, the specific allergen is formulated with an adjuvant, most often in the form of aluminium hydroxide (AlOH). It has been shown that allergen-specific IgG antibodies are induced as a result of successful SIT. Objective To investigate the possibility of optimizing the formulation of AlOH-based grass-pollen allergy vaccines for SCIT in a way that allows for shorter updosing regimens while maintaining the immunogenicity of the vaccine. Methods Mice were immunized with…

AllergyInjections SubcutaneousT-LymphocytesT cellmedicine.medical_treatmentImmunologyAluminum HydroxidePharmacologyPoaceaemedicine.disease_causePhleumMiceAllergenAdjuvants ImmunologicAnimalsHumansImmunology and AllergyMedicineMice Inbred BALB CbiologyPlant Extractsbusiness.industryImmunogenicityRhinitis Allergic SeasonalAllergen extractAllergensmedicine.diseasebiology.organism_classificationTreatment Outcomemedicine.anatomical_structureDesensitization ImmunologicImmunoglobulin GPhleumImmunologybiology.proteinPollenFemaleAntibodybusinessAdjuvantClinical & Experimental Allergy
researchProduct

Zanhasaponins A and B, Antiphospholipase A2 Saponins from an Antiinflammatory Extract of Zanha africana Root Bark

1997

A MeOH extract from Z. africana was examined for topical antiinflammatory activity and proved to be active against arachidonic acid (AA) acute edema, 12-O-tetradecanoylphorbol 13-acetate (TPA)-induced chronic inflammation, and oxazolone delayed-type hypersensitivity in mice. The extract also showed significant inhibitory activity of Naja naja phospholipase A2 when a polarographic method was used. Two oleanane-type triterpene saponins, zanhasaponins A (1) and B (2), and the cyclitol pinitol (4), isolated from the extract, were active as inhibitors of PLA2. A further saponin, zanhasaponin C (3) was inactive in this assay.

Anti-Inflammatory AgentsSaponinPharmaceutical SciencePharmacognosyDermatitis ContactPhospholipases AAnalytical ChemistryMicechemistry.chemical_compoundPhospholipase A2Adjuvants ImmunologicTriterpeneDrug DiscoveryAnimalsEdemaEnzyme InhibitorsPeroxidaseSkinPharmacologychemistry.chemical_classificationintegumentary systembiologyTraditional medicineOrganic ChemistryOxazoloneGlycosideSaponinsTriterpenesTerpenoidPhospholipases A2Complementary and alternative medicinechemistryBiochemistryvisual_artvisual_art.visual_art_mediumbiology.proteinTetradecanoylphorbol AcetateMolecular MedicineFemaleBarkArachidonic acidJournal of Natural Products
researchProduct

HPMA-Based Nanocarriers for Effective Immune System Stimulation.

2019

The selective activation of the immune system using nanoparticles as a drug delivery system is a promising field in cancer therapy. Block copolymers from HPMA and laurylmethacrylate-co-hymecromone-methacrylate allow the preparation of multifunctionalized core-crosslinked micelles of variable size. To activate dendritic cells (DCs) as antigen presenting cells, the carbohydrates mannose and trimannose are introduced into the hydrophilic corona as DC targeting units. To activate DCs, a lipophilic adjuvant (L18-MDP) is incorporated into the core of the micelles. To elicit an immune response, a model antigen peptide (SIINFEKL) is attached to the polymeric nanoparticle-in addition-via a click rea…

AzidesPolymers and PlasticsOvalbuminPolymersMannoseBioengineering02 engineering and technology010402 general chemistry01 natural sciencesMicelleBiomaterialschemistry.chemical_compoundDrug Delivery SystemsAntigenAdjuvants ImmunologicMaterials ChemistryHumansParticle SizeAntigen-presenting cellMicellesMannanChemistryDendritic Cells021001 nanoscience & nanotechnologyPeptide Fragments0104 chemical sciencesImmune SystemDrug deliveryBiophysicsMethacrylatesNanoparticlesClick ChemistryNanocarriers0210 nano-technologyHydrophobic and Hydrophilic InteractionsMannose receptorBiotechnologyMacromolecular bioscience
researchProduct